Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3DNA-Wnt agonist
- Development stage
- Preclinical
- Lead developer
- Genisphere
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal, Intracerebroventricular, Intravenous, Parenteral (infusion)
01
Overview
**3DNA-Wnt agonist** is an experimental nanotherapeutic developed by **Genisphere** using its proprietary **3DNA** synthetic DNA nanocarrier platform to deliver a **Wnt pathway agonist peptide** to **microglia** in the injured brain. The construct is designed to maintain or restore **Wnt beta-catenin signaling** in activated microglia, thereby limiting acquisition of a pro-inflammatory phenotype that contributes to white matter and myelin injury. It has been described in preclinical research in collaboration with **Inserm** for prevention or treatment of **neuroinflammation-associated brain injury in preterm infants**, particularly encephalopathy of prematurity and related myelin damage. The product is best characterized as a **nanoparticle nucleic acid scaffold conjugated to a peptide agonist**, rather than a conventional small molecule or marketed pharmaceutical product.
- Other names
- 3DNA Wnt agonist3DNA nanocarrier-delivered Wnt agonistmicroglia-targeted 3DNA-Wnt agonistmicroglia-targeted3DNA-Wnt agonistmicroglia-targeted-3DNA-Wnt agonist
02
Targets
GSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on 3DNA-Wnt agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3DNA-Wnt agonist.